International guideline recommends sebetralstat as first-line acute therapy for adolescents with hereditary angioedema

A newly published international guideline on the diagnosis and management of pediatric hereditary angioedema (HAE) provides updated, evidence-based recommendations for children and adolescents with HAE due to C1 inhibitor deficiency (HAE-C1INH), including a strong recommendation for sebetralstat as a first-line option for acute treatment in adolescents 12 years and older.^1,2